MS Patient With Relpasing Remitting Attacks Clinical Trial
Official title:
Nasal Administration of Dexamethasone for MS Treatment
| Verified date | May 2008 |
| Source | Hadassah Medical Organization |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Israel: Ministry of Health |
| Study type | Interventional |
The study aims to assess the safety and efficacy of nasale administration of Dexamethasone in relapsing MS patients
| Status | Withdrawn |
| Enrollment | 10 |
| Est. completion date | January 2009 |
| Est. primary completion date | December 2008 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - MS patients with esatblished relapsing remitting attacks - increase in EDSS of at least 1 point for a least one day Exclusion Criteria: - children under 18 - pregnant patients - patients with diabetes - known allergy to steroids - patients who received steroids within 3 months prior to the study |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Israel | Hadassah Medical Organization | Jerusalem |
| Lead Sponsor | Collaborator |
|---|---|
| Hadassah Medical Organization |
Israel,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | reduction in the EDSS functional system score | four months | No |